The case for intrarenal hypertension in the initiation and progression of diabetic and other glomerulopathies.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Who cites it

164 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Role of microRNAs in the Therapeutic Effects of Curcumin in Non-Cancer Diseases.Molecular diagnosis & therapy · 2016
   Pooled it
2. Captopril and atenolol are equally effective in retarding progression of diabetic nephropathy. Results of a 2-year prospective, randomized study.Diabetologia · 1994
   Trial
3. Long-term treatment with nifedipine reduces urinary albumin excretion and glomerular filtration rate in normotensive type 1 diabetic patients with microalbuminuria.Acta diabetologica · 1994
   Trial
4. Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy.Diabetologia · 1992
   Trial
5. UK Prospective Diabetes Study (UKPDS). VIII. Study design, progress and performance.Diabetologia · 1991
   Trial
6. Differential effects of enalapril and atenolol on proteinuria and renal haemodynamics in non-diabetic renal disease.BMJ (Clinical research ed.) · 1991
   Trial
7. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria.BMJ (Clinical research ed.) · 1991
   Trial
8. Effect of captopril on blood pressure and kidney function in normotensive insulin dependent diabetics with nephropathy.BMJ (Clinical research ed.) · 1989
   Trial
9. Enalapril does not alter renal function in normotensive, normoalbuminuric, hyperfiltering type 1 (insulin-dependent) diabetic children.Diabetologia · 1989
   Trial
10. Treating hypertension in black compared with white non-insulin dependent diabetics: a double blind trial of verapamil and metoprolol.BMJ (Clinical research ed.) · 1988
    Trial
11. Protection of kidney function and decrease in albuminuria by captopril in insulin dependent diabetics with nephropathy.BMJ (Clinical research ed.) · 1988
    Trial
12. Converting enzyme inhibition and kidney function in normotensive diabetic patients with persistent microalbuminuria.British medical journal (Clinical research ed.) · 1987
    Trial
13. Effect of near normoglycaemia for two years on progression of early diabetic retinopathy, nephropathy, and neuropathy: the Oslo study.British medical journal (Clinical research ed.) · 1986
    Trial
14. Acute reduction of arterial blood pressure reduces urinary albumin excretion in type 1 (insulin-dependent) diabetic patients with incipient nephropathy.Diabetologia · 1986
    Trial
15. Exploring the renoprotective potential of Beta vulgaris in diabetic nephropathy: an integrated network pharmacology, molecular docking and dynamics simulation study.Molecular diversity · 2026
    Article
16. Potential Molecular Biomarkers for Predicting and Monitoring Complications in Type 2 Diabetes Mellitus.Molecules (Basel, Switzerland) · 2025
    Review
17. SGLT2 inhibitors: cardiorenal metabolic drugs for the ages.The Journal of clinical investigation · 2024
    Article
18. Calcineurin Is a Universal Regulator of Vessel Function-Focus on Vascular Smooth Muscle Cells.Cells · 2023
    Review
19. Neutralizing MIP3The Journal of pharmacology and experimental therapeutics · 2023
    Article
20. Urine Immunoglobin G Greater Than 2.45 mg/L Has a Correlation with the Onset and Progression of Diabetic Kidney Disease: A Retrospective Cohort Study.Journal of personalized medicine · 2023
    Article

104 more citing papers are in PubMed but not listed here.

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as